ABSTRACT
PURPOSE: In this study, the antiproliferative effects of the aromatase inhibitor anastrozole (arimidex®) was evaluated on estrogen receptor (ER) positive FM3A cell line originated from C3H mouse mammary carcinoma. METHODS: For this purpose cell kinetic parameters including viability analysis, mitotic index and labelling index were used. Three different doses of anostrozole (D1= 0.01 µM, D2= 0.1µM, D3= 1µM) were applied to cells for 24 h to determine the most effective dose. A dose of 1µM dose was determined as the most effective and this was used in all subsequent applications for 0-72 h. RESULTS: The results showed that there was a significant decrease in viability, mitotic index and labelling index for all experimental groups. The differences between control and all experimental groups were statistically significant (p<0.01) for all applications. CONCLUSIONS: Anastrozole offers a promising treatment modality in estrogen sensitive breast cancer.
